Semaglutide (compounded) Reference
Educational, not medical advice reference for Semaglutide (compounded): GLP-1, Fat Loss; regulatory status, evidence posture, source review, and…
Plain English
- What it is
- Semaglutide is the medicine inside the brand-name drugs Ozempic and Wegovy. It is usually a weekly self-injection, and one brand (Rybelsus) comes as a daily pill instead. Compounding pharmacies and some telehealth sellers make their own copies, often as a liquid in a vial that is drawn up into a syringe.
- What people use it for
- People mainly reach for it for weight loss. The compounded copies grew popular when the brand-name versions were hard to get during a national shortage.
- What the science shows
- The brand-name versions went through FDA review before they could be sold. The compounded copies did not. The FDA does not review compounded drugs for safety, effectiveness, or quality before they reach patients, so what is actually in a compounded vial can vary from one pharmacy to the next.
- The catch
- Compounded semaglutide is not FDA-approved and is not the same FDA-reviewed product as the brands. The FDA has received many reports of measurement errors with compounded vials, some serious enough to require hospitalization, often because people drew up far more than intended or got confused between units. The FDA has also flagged fake products and unapproved salt forms, and in 2026 it proposed excluding semaglutide from large-scale (503B) compounding.
Reference summary
pepSmart uses approved-label semaglutide schedules only as reference context; compounded vial concentration and syringe-unit instructions must come from the prescriber or dispensing pharmacy.
Regulatory and posture
- Categories
- GLP-1, Fat Loss
- Aliases
- Semaglutide, Wegovy label reference, Ozempic active ingredient, Rybelsus
- Evidence posture
- human
- Regulatory status
- Compounded semaglutide is not FDA-approved. FDA-approved semaglutide label references exist for branded products, including Wegovy injection and Wegovy HD 7.2 mg for certain adults. The FDA semaglutide shortage was resolved in February 2025; with semaglutide off the shortage list, large-scale compounding of copies is restricted, and in April 2026 the FDA proposed excluding semaglutide from the 503B outsourcing-facility bulks list (public comment open through June 29, 2026). Patient-specific 503A compounding remains the narrow lawful pathway.
- Content review status
- approved label reference
Selected public sources
- Novo Nordisk Wegovy dosing reference
- Novo Nordisk Wegovy safety profile
- FDA Wegovy HD 7.2 mg approval announcement
- FDA: proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list (April 2026)
- FDA concerns with unapproved GLP-1 drugs
Related tools
- Semaglutide dose calculator - Run semaglutide-focused vial draw math.
- GLP-1 conversion calculator - Convert a GLP-1 mg dose to U-100 units and ml.
- GLP-1 ramp planner - Preview a linear educational dose-step table.
- Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.
- PK simulator overview - Public overview of the Pro pharmacokinetic simulator.
- GLP-1 taper planner overview - Public overview of the Pro GLP-1 taper planner.
For research and educational purposes only. Not medical advice.